

Resource Summary Report

Generated by [kravitz2](#) on Aug 2, 2026

Selleck Chemicals LLC

RRID:SCR_003823

Type: Tool

Proper Citation

Selleck Chemicals LLC (RRID:SCR_003823)

Resource Information

URL: <http://www.selleckchem.com/>

Proper Citation: Selleck Chemicals LLC (RRID:SCR_003823)

Description: An Antibody supplier

Synonyms: Selleck Chemicals

Resource Type: commercial organization

Keywords: antibody, chemical supply, selleck chemicals

Resource Name: Selleck Chemicals LLC

Resource ID: SCR_003823

Alternate IDs: nlx_152457

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260801T190220+0000

Ratings and Alerts

No rating or validation information has been found for Selleck Chemicals LLC.

No alerts have been found for Selleck Chemicals LLC.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 192 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Khan MA, et al. (2026) Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. *Cancer letters*, 638, 218160.

Kim DK, et al. (2025) Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab. *Molecular cancer therapeutics*, 24(3), 354.

Chawla Y, et al. (2025) Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels. *Cancer & metabolism*, 13(1), 9.

Bibi N, et al. (2025) Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry. *PloS one*, 20(2), e0310855.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Özen I, et al. (2025) Traumatic brain injury causes early aggregation of beta-amyloid peptides and NOTCH3 reduction in vascular smooth muscle cells of leptomeningeal arteries. *Acta neuropathologica*, 149(1), 10.

Gu Z, et al. (2025) Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4. *Journal of biomedical science*, 32(1), 36.

Li Y, et al. (2025) MolPrompt: improving multi-modal molecular pre-training with knowledge prompts. *Bioinformatics (Oxford, England)*, 41(9).

Caro EJGV, et al. (2025) Overcoming Clusterin-Induced Chemoresistance in Cancer: A Computational Study Using a Fragment-Based Drug Discovery Approach. *Biology*, 14(6).

Jia Y, et al. (2025) A phase separation-related gene signature for prognosis prediction and immunotherapy response evaluation in gastric cancer with targeted natural compound discovery. *Discover oncology*, 16(1), 1393.

Sinha S, et al. (2025) DeepTarget predicts anti-cancer mechanisms of action of small molecules by integrating drug and genetic screens. *NPJ precision oncology*, 9(1), 340.

Agostini G, et al. (2025) Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids. *Frontiers in cell and developmental biology*, 13, 1631116.

Loganathan T, et al. (2025) Computational molecular insights into ibrutinib as a potent inhibitor of HER2-L755S mutant in breast cancer: gene expression studies, virtual screening, docking, and molecular dynamics analysis. *Frontiers in molecular biosciences*, 12, 1510896.

Wang Y, et al. (2025) Homeodomain protein PRRX1 anchors the Ku heterodimers at DNA double-strand breaks to promote nonhomologous end-joining. *Nucleic acids research*, 53(6).

Noronha-Matos JB, et al. (2025) Differential participation of CaMKII/ROCK and NOS pathways in the cholinergic inhibitory drive operated by nicotinic $\alpha 7$ receptors in perisynaptic Schwann cells. *Biochemical pharmacology*, 231, 116649.

Mundi PS, et al. (2025) Systematic elucidation and pharmacologic targeting on non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor. *bioRxiv* : the preprint server for biology.

Khathayer F, et al. (2024) Mocetinostat as a novel selective histone deacetylase (HDAC) inhibitor in the promotion of apoptosis in glioblastoma cell line C6 and T98G. *Research square*.

Recchia AD, et al. (2024) Pharmacological targeting of smoothened receptor cysteine-rich domain by Budesonide promotes in vitro myelination. *Frontiers in molecular neuroscience*, 17, 1473960.

Kritsi E, et al. (2024) A Computational Approach for the Discovery of Novel DNA Methyltransferase Inhibitors. *Current issues in molecular biology*, 46(4), 3394.

Wang R, et al. (2024) Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 11(9), e2304939.